This matter involved scientific tests for generic drug closeness to the brand, as required by the FDA. The plaintiff alleged deceptive conduct within the standards organization (the US Pharmacopeial Convention or USP) responsible for the generic test specifications. The specific antitrust allegation was that the conduct had led to market foreclosure of generic competition. A CRA expert provided economic analysis of the SDO’s IPR policy and analysis of the economic impact of the alleged breach of that policy.
Four US Competition experts recognized as Global Elite Thought Leaders by Who's Who Legal
CRA is proud to announce that Andrew Dick, Elizabeth Bailey, Michelle Burtis, and Steven Salop have been recognized as Global Elite Thought Leaders in...